Abstract
Perimenopausal women, often in the peak-earning years of their careers, make up a significant proportion of the workforce, with women aged 40-49 accounting for approximately 21% of the U.S. female workforce. Previous studies have revealed perimenopause to be associated with psychological, vasomotor, somatic, and cognitive symptoms that affect women’s quality of life, yet its workplace and economic consequences remain under-explored. We examined work impairment by symptom severity and across reproductive stages in a cross-sectional survey of U.S. women aged 35-59 (n=945), using the Work Productivity and Activity Impairment questionnaire and Menopause Rating Scale. We then estimated associated productivity losses using a human capital approach.
Perimenopausal women were equally likely to remain in the labour force as premenopausal women (76.6% vs. 78.0%) but reported substantially higher work impairment (22.5% vs. 12.7%). Work impairment rose from 3.4% among women with minimal symptoms to 33.4% among those with severe symptoms and was driven predominantly by presenteeism rather than absenteeism. Somatic and psychological symptoms showed the strongest associations with work impairment, whereas urogenital symptoms were not significantly associated. The observed work impairment translated into an estimated annual productivity loss of approximately $6,061 per woman in perimenopause and a societal burden of $56.7 billion in the United States. These findings suggest that perimenopause is a substantial but under-recognised workplace health challenge that requires tailored, symptom-matched, workforce support.
Competing Interest Statement
Y.X., A.C.C., L.Z. are current employees of Flo Health. Y.X., Y.H-M, A.C.C., and L.Z. hold equity interests in Flo Health. C.P. is consultant for Flo Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Western Copernicus Group Institutional Review Board approved this study (IRB No. 20250554).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version has been revised to clarify the recruitment and eligibility criteria, demographic measures, and statistical analysis. The analytical approach has been clarified to specify that reproductive stage and symptom severity were examined in separate multivariable models. Figure 1 has been revised to clarify participant flow and exclusions. Additional results and supplementary analyses have been added, including a comparison of employed and unemployed participants, and table descriptions have been expanded for clearer interpretation. The Discussion has been revised to provide broader guidance on workplace support and to address equity and changing support needs. The limitations have also been expanded to address sample representativeness and the lack of occupational and workplace context.
Abbreviations
- BMI
- Body Mass Index
- BLS
- Bureau of Labor Statistics
- CI
- Confidence Interval
- EQ-5D-5L
- EuroQol five-dimensional, five-level questionnaire
- HRQoL
- Health-related quality of life
- IRB
- Institutional Review Board
- MRS
- Menopause Rating Scale
- SD
- Standard Deviation
- WPAI
- Work Productivity and Activity Impairment questionnaire
